Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes (MELAS)
Overview
Plain-Language Overview
Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes (MELAS) is a rare genetic disorder that affects the body's energy production system, primarily involving the brain and muscles. It is caused by problems in the mitochondria, which are the parts of cells responsible for producing energy. People with MELAS often experience episodes similar to strokes, which can cause sudden weakness, vision problems, and seizures. The condition also leads to a buildup of lactic acid in the body, causing fatigue and muscle pain. Over time, MELAS can affect multiple organs and lead to progressive neurological decline. It is inherited through mitochondrial DNA, which is passed down from the mother. The symptoms usually begin in childhood or early adulthood and can vary widely in severity.
Clinical Definition
Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes (MELAS) is a mitochondrial disorder characterized by defects in mitochondrial oxidative phosphorylation, most commonly due to mutations in the MT-TL1 gene encoding mitochondrial tRNA for leucine. This leads to impaired ATP production and increased lactic acid accumulation, causing cellular energy failure. Clinically, MELAS presents with recurrent stroke-like episodes that do not correspond to typical vascular territories, progressive encephalopathy, seizures, and lactic acidosis. Additional features include muscle weakness, hearing loss, diabetes mellitus, and short stature. The disease is maternally inherited due to the transmission of mutated mitochondrial DNA. MELAS is significant for its multisystem involvement and progressive neurological deterioration, often leading to severe disability or death.
Inciting Event
Metabolic stress such as infection or fasting can trigger stroke-like episodes.
Physical or emotional stress may precipitate acute neurologic deterioration.
Certain medications, especially valproic acid, can worsen mitochondrial dysfunction.
Episodes may be triggered by vigorous exercise due to increased energy demand.
Latency Period
Symptoms typically develop in childhood or adolescence after a latent period of normal development.
Stroke-like episodes often occur years after initial nonspecific symptoms such as exercise intolerance.
Lactic acidosis and neurologic symptoms may progress over months to years before diagnosis.
Variable latency due to heteroplasmy and tissue distribution of mutated mitochondria.
Diagnostic Delay
Initial symptoms are often nonspecific and mimic other neurologic or metabolic disorders.
Lack of awareness of mitochondrial diseases leads to misdiagnosis as stroke or epilepsy.
Variable presentation and heteroplasmy complicate genetic testing interpretation.
Limited access to specialized mitochondrial DNA analysis delays confirmation.
Overlap with other neurometabolic syndromes causes diagnostic confusion.
Clinical Presentation
Signs & Symptoms
Recurrent stroke-like episodes with transient hemiparesis and seizures
Progressive sensorineural hearing loss
Exercise intolerance and muscle weakness due to mitochondrial myopathy
Headache and vomiting during acute metabolic crises
Cognitive decline and dementia in advanced disease
History of Present Illness
Recurrent stroke-like episodes with transient hemiparesis, seizures, and cortical blindness are hallmark features.
Progressive muscle weakness and exercise intolerance develop over time.
Episodes of headache, vomiting, and altered mental status often precede stroke-like events.
Chronic symptoms include sensorineural hearing loss and cognitive decline.
History may reveal diabetes mellitus or short stature as associated features.
Past Medical History
Previous episodes of seizures or transient ischemic attacks are common.
History of lactic acidosis or unexplained metabolic acidosis during illness.
Prior diagnosis of hearing loss or diabetes mellitus may be present.
No history of vascular risk factors typical for ischemic stroke.
Possible history of developmental delay or learning difficulties.
Family History
Maternal relatives may have a history of mitochondrial disorders or similar neurologic symptoms.
Family members may exhibit sensorineural hearing loss, diabetes, or cardiomyopathy.
Inheritance pattern is maternal, with no male-to-offspring transmission.
Variable expression among family members due to heteroplasmy.
Some relatives may have been misdiagnosed with stroke or epilepsy.
Physical Exam Findings
Short stature and muscle weakness due to mitochondrial myopathy
Sensorineural hearing loss detected by audiometry
Stroke-like neurological deficits including hemiparesis and cortical blindness
Lactic acidosis signs such as tachypnea and altered mental status
Ophthalmoplegia and retinopathy on fundoscopic exam
Diagnostic Workup
Diagnostic Criteria
Diagnosis of MELAS is established by a combination of clinical, laboratory, and genetic findings. Key diagnostic criteria include the presence of stroke-like episodes before age 40, lactic acidosis in blood or cerebrospinal fluid, and evidence of mitochondrial dysfunction on muscle biopsy (e.g., ragged-red fibers). Neuroimaging typically shows stroke-like lesions that do not conform to vascular territories. Definitive diagnosis is confirmed by identifying pathogenic mutations in mitochondrial DNA, most commonly the m.3243A>G mutation in the MT-TL1 gene.
Pathophysiology
Key Mechanisms
Mitochondrial DNA mutations impair oxidative phosphorylation leading to decreased ATP production.
Defective mitochondrial respiratory chain complexes, especially complex I and IV, cause energy failure in high-demand tissues.
Lactic acidosis results from increased anaerobic glycolysis due to impaired aerobic metabolism.
Stroke-like episodes arise from mitochondrial dysfunction causing neuronal energy deficits and vasogenic edema.
Heteroplasmy of mutated mitochondrial DNA leads to variable phenotypic expression and tissue involvement.
| Involvement | Details |
|---|---|
| Organs | Brain involvement manifests as stroke-like episodes, seizures, and cognitive decline in MELAS. |
Muscle involvement causes myopathy and exercise intolerance due to mitochondrial dysfunction. | |
Heart may be affected with cardiomyopathy secondary to mitochondrial energy defects. | |
| Tissues | Brain tissue is vulnerable to energy failure causing stroke-like episodes and encephalopathy. |
Skeletal muscle tissue shows mitochondrial abnormalities leading to weakness and exercise intolerance. | |
| Cells | Neurons are critically affected due to their high energy demand and reliance on mitochondrial ATP production. |
Skeletal muscle cells exhibit dysfunction leading to myopathy and exercise intolerance in MELAS. | |
| Chemical Mediators | Lactic acid accumulates due to impaired oxidative phosphorylation causing metabolic acidosis. |
Nitric oxide levels are reduced, contributing to endothelial dysfunction and stroke-like episodes. |
Treatments
Pharmacological Treatments
L-arginine
- Mechanism:
Enhances nitric oxide production to improve endothelial function and reduce stroke-like episodes.
- Side effects:
Hypotension
Gastrointestinal upset
- Clinical role:
First-line
Coenzyme Q10
- Mechanism:
Supports mitochondrial electron transport chain function to improve cellular energy production.
- Side effects:
Mild gastrointestinal discomfort
Rash
- Clinical role:
Adjunctive
L-carnitine
- Mechanism:
Facilitates fatty acid transport into mitochondria to enhance energy metabolism.
- Side effects:
Fishy body odor
Gastrointestinal upset
- Clinical role:
Adjunctive
Antiepileptic drugs (e.g., levetiracetam)
- Mechanism:
Controls seizures by modulating neuronal excitability.
- Side effects:
Drowsiness
Behavioral changes
- Clinical role:
Supportive
Non-pharmacological Treatments
Avoidance of metabolic stressors such as fasting and excessive exercise to reduce mitochondrial demand.
Supportive care including physical therapy to manage neuromuscular symptoms and maintain function.
Nutritional support with a balanced diet rich in antioxidants to support mitochondrial health.
Prevention
Pharmacological Prevention
L-arginine supplementation to improve endothelial function and reduce stroke-like episodes
Coenzyme Q10 and other mitochondrial cofactors to enhance oxidative phosphorylation
Antiepileptic drugs to prevent seizures during stroke-like episodes
Antioxidants such as vitamin E to reduce oxidative stress
Avoidance of mitochondrial toxins like valproic acid to prevent worsening
Non-pharmacological Prevention
Avoidance of metabolic stressors such as fasting and infections to reduce crises
Regular monitoring with MRI and lactate levels to detect early stroke-like episodes
Hearing aids and speech therapy for sensorineural hearing loss
Physical therapy to maintain muscle strength and function
Genetic counseling for affected families due to maternal inheritance pattern
Outcome & Complications
Complications
Recurrent strokes causing permanent neurological deficits
Seizure disorders with risk of status epilepticus
Progressive sensorineural deafness leading to deafness
Cardiac conduction defects and heart failure
Severe lactic acidosis causing metabolic crisis and multi-organ failure
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes (MELAS) versus Leigh Syndrome
Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes (MELAS) | Leigh Syndrome |
|---|---|
Childhood to young adult onset with stroke-like episodes and progressive encephalopathy | Infantile or early childhood onset with rapid neurodegeneration |
Stroke-like lesions not confined to vascular territories on MRI | Bilateral symmetric lesions in basal ganglia and brainstem on MRI |
Mitochondrial DNA point mutations (e.g., m.3243A>G in MT-TL1) detected by genetic testing | Defects in mitochondrial respiratory chain complexes I, II, or IV on muscle biopsy or enzymatic assay |
Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes (MELAS) versus Ischemic Stroke
Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes (MELAS) | Ischemic Stroke |
|---|---|
Stroke-like lesions crossing vascular territories on brain MRI | Lesions confined to specific vascular territories on brain MRI or CT |
Recurrent stroke-like episodes with partial recovery and fluctuating symptoms | Sudden onset focal neurological deficits with permanent deficits |
Elevated serum and CSF lactate levels indicating lactic acidosis | Normal or mildly elevated lactate levels |
Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes (MELAS) versus Multiple Sclerosis
Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes (MELAS) | Multiple Sclerosis |
|---|---|
Cortical and subcortical stroke-like lesions without typical demyelinating plaques | Multiple periventricular white matter plaques with Dawson fingers on MRI |
Stroke-like episodes with metabolic encephalopathy and lactic acidosis | Relapsing-remitting neurological deficits with demyelination |
Mitochondrial DNA mutation analysis positive | Oligoclonal bands in CSF |
Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes (MELAS) versus Hereditary Stroke-like Migraine Attacks with Encephalopathy and Seizures (HSEMS)
Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes (MELAS) | Hereditary Stroke-like Migraine Attacks with Encephalopathy and Seizures (HSEMS) |
|---|---|
Mitochondrial (maternal) inheritance pattern | Autosomal dominant inheritance |
Elevated lactate in blood and CSF | Normal lactate levels |
Stroke-like lesions not restricted to vascular territories with mitochondrial dysfunction | Cortical spreading depression with transient MRI changes |
Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes (MELAS) versus Wilson Disease
Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes (MELAS) | Wilson Disease |
|---|---|
Childhood to young adult onset with stroke-like episodes and lactic acidosis | Adolescence or young adulthood with hepatic and neuropsychiatric symptoms |
Elevated serum and CSF lactate without copper metabolism abnormalities | Low serum ceruloplasmin and elevated 24-hour urinary copper |
Stroke-like lesions in cortex and subcortical regions not typical for Wilson disease | Basal ganglia abnormalities including the 'face of the giant panda' sign on MRI |